undamentalytics Newsletter
Sign in

60 Degrees Pharmaceuticals, Inc. revenue

60 Degrees Pharmaceuticals, Inc.'s revenue was $1.0m in fiscal 2025, up 65.5% on the year before. Since fiscal 2022 ($223,208) it has grown at a compound 65.2% a year. Over the last twelve months it was $1.1m.

Revenue history

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue2232546081,0051,111
Growth on the year before—+13.6%+139.6%+65.5%—
Gross profit−209−221223224216

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Pharmaceuticals: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
60 Degrees Pharmaceuticals, Inc. $1.1m 73.2% 74.9%
China SXT Pharmaceuticals, Inc. $1.1m -34.6% —
Scienture Holdings, Inc. $821,315 540.6% -58.5%
Lipocine Inc. $1.6m -62.7% 205.6%
Nutriband Inc. $1.6m -37.3% -10.8%
Eyepoint, Inc. $2.8m -94.6% -57.9%

Compare with peers

Head to head: SXTC vs SXTPSCNX vs SXTPLPCN vs SXTPNTRB vs SXTP

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from 60 Degrees Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to 60 Degrees Pharmaceuticals, Inc.